Want to see TSE:LOBE full AI Analyst Report?
Top Page
Lobe Sciences
(LOBE)
Select Model
Select Model
Rating:43Neutral
Price Target:
C$0.05
▼(-33.75% Downside)
Action:Reiterated
Date:10/01/26
The score is held down primarily by weak financial performance: zero TTM revenue, widening losses, and increased cash burn that heightens financing risk. Technicals also remain unfavorable with the stock trading below major moving averages and negative MACD. Valuation provides limited support due to a negative P/E and no stated dividend yield.
Positive Factors
Equity Stabilization
The return to positive equity marks a meaningful improvement from the company’s earlier balance-sheet weakness. Although capital remains volatile, this stabilization provides a stronger base for financing, partnerships, and continued development than the negative-equity position reported in prior years.
Negative Factors
No Current Revenue
The absence of current revenue shows that Lobe Sciences does not presently have a functioning commercial revenue base supporting its operations. This weakens visibility into future self-funded growth and leaves successful development, commercialization, or partnering as essential to rebuilding durable earnings capacity.
Read all positive and negative factors
Positive Factors
Negative Factors
Equity Stabilization
The return to positive equity marks a meaningful improvement from the company’s earlier balance-sheet weakness. Although capital remains volatile, this stabilization provides a stronger base for financing, partnerships, and continued development than the negative-equity position reported in prior years.
Read all positive factors
Lobe Sciences (LOBE) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$16.95M
Dividend YieldN/A
Average Volume (3M)47.26K
Price to Earnings (P/E)―
Beta (1Y)0.25
Revenue GrowthN/A
EPS Growth31.00%
CountryCA
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding308,182,160
10 Day Avg. Volume83,651
30 Day Avg. Volume47,259
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-4.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Lobe Sciences Business Overview & Revenue Model
Company Description
Lobe Sciences Ltd. operates as a life sciences entity, primarily focused on the exploration and advancement of psychedelic pharmaceutical compounds. The company is actively engaged in formulating psilocybin-derived therapeutics, combined with N-ac...
How the Company Makes Money
Publicly available, reliably current information needed to describe Lobe Sciences’ present-day revenue model (e.g., active commercial products, recurring service revenues, licensing royalties, or material collaboration income) is null. In general,...
Lobe Sciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
16
Very Negative
| Breakdown | TTM | Nov 2025 | Nov 2024 | Aug 2023 | Nov 2022 | Nov 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 136.21K | 840.53K | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 134.45K | 772.83K | -10.22K | 0.00 |
| EBITDA | -6.89M | -4.27M | -4.12M | -4.40M | -11.96M | -6.16M |
| Net Income | -5.17M | -4.43M | -4.42M | -4.71M | -12.25M | -22.82M |
Balance Sheet | ||||||
| Total Assets | 5.53M | 7.59M | 258.57K | 2.30M | 1.75M | 12.10M |
| Cash, Cash Equivalents and Short-Term Investments | 5.21M | 7.54M | 237.77K | 140.29K | 907.54K | 7.43M |
| Total Debt | 338.40K | 273.35K | 1.75M | 332.64K | 0.00 | 0.00 |
| Total Liabilities | 2.33M | 2.70M | 3.37M | 2.46M | 1.30M | 804.70K |
| Stockholders Equity | 1.89M | 2.36M | -3.11M | -160.13K | 445.69K | 11.29M |
Cash Flow | ||||||
| Free Cash Flow | -3.74M | -1.42M | -462.29K | -1.72M | -2.73M | -5.04M |
| Operating Cash Flow | -3.74M | -1.42M | -462.29K | -1.72M | -2.73M | -5.04M |
| Investing Cash Flow | -3.78M | 6.56M | 0.00 | 0.00 | 1.74M | 1.07M |
| Financing Cash Flow | 1.09M | 514.40K | 563.51K | 950.01K | 753.12K | 4.92M |
Lobe Sciences Technical Analysis
Negative
0.08
Price Trends
0.08
Negative
0.09
Negative
0.08
Negative
Market Momentum
>-0.01
Positive
32.06
Neutral
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:LOBE, the sentiment is Negative. The current price of 0.08 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.08, and above the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 32.06 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:LOBE.
Lobe Sciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | C$29.90M | -6.03 | -13.79% | ― | -6.74% | 43.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | C$4.26M | -2.19 | -43.92% | ― | -18.30% | -397.37% | |
43 Neutral | C$16.95M | -2.67 | -338.76% | ― | ― | 31.00% | |
42 Neutral | C$12.02M | -4.07 | -35.33% | ― | -1.41% | -78.91% | |
41 Neutral | C$10.28M | -2.94 | 28.59% | ― | 0.90% | 57.73% | |
41 Neutral | C$13.44M | -3.09 | -108.44% | ― | -0.23% | -142.54% |
* Healthcare Sector Average
TSE:LOBE
Lobe Sciences
0.06
<0.01
10.00%
TSE:LABS
MediPharm Labs
0.07
>-0.01
-6.67%
TSE:PCLO
PharmaCielo
0.06
0.01
22.22%
TSE:OILS
Nextleaf Solutions
0.03
-0.05
-64.29%
TSE:AVCN
Avicanna
0.10
-0.17
-62.96%
TSE:GWAY
Greenway Greenhouse Cannabis Corp.
0.09
-0.10
-52.63%
Lobe Sciences Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Lobe Sciences Raises $2.16 Million in Upsized Private Placement to Advance Sickle Cell Drug
Positive
Sep 1, 2026
Lobe Sciences has closed an upsized, non-brokered private placement of common shares at $0.085 per share, issuing a total of 25,411,762 shares for gross proceeds of $2.16 million following strong investor demand. The second tranche added 705,882 s...
Business Operations and StrategyPrivate Placements and Financing
Lobe Sciences Upsizes Private Placement to Fund Sickle Cell and Neurology Pipeline
Positive
Aug 29, 2026
Lobe Sciences has increased the size of its non-brokered private placement of common shares at $0.085, following strong investor demand. After closing a first tranche that raised $2.1 million, the company plans a second tranche that will bring tot...
Business Operations and StrategyExecutive/Board Changes
Lobe Sciences Names New CFO to Support Growth and Clinical Pipeline
Positive
Aug 28, 2026
Lobe Sciences, a clinical-stage biopharmaceutical company developing differentiated therapies for serious unmet medical needs, is advancing a pipeline led by L-130, a conjugated psilocin compound for chronic cluster headache, and S-100 for sickle ...
Business Operations and StrategyPrivate Placements and Financing
Lobe Sciences Raises $2.1 Million to Advance Sickle Cell Drug Toward Clinical Trials
Positive
Aug 20, 2026
Lobe Sciences Ltd., a Vancouver-based clinical-stage biopharmaceutical company, develops treatments for unmet medical needs via subsidiaries focused on neurological, psychiatric and hematologic disorders. Through Cynaptec Pharmaceuticals it is adv...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.